High blood pressure (BP) contributes the greatest attributable risk to mortality worldwide. However, evidence on economically efficient strategies to lower BP from low-and middle-income countries remains scarce. The Control of Blood Pressure and Risk Attenuation (COBRA) trial randomized 1341 hypertensive subjects in 12 randomly selected communities in Karachi, Pakistan, to 3 intervention programs compared with usual care: (1) combined home health education (HHE) by lay health workers plus management by trained general practitioners (GPs); (2) HHE only; and (3) trained GPs only. The HHE intervention was modeled on the existing Lady Health Workers Program in Pakistan and provided education on healthy diet, physical activity, and tobacco cessation in the home setting at 3-month intervals. GP training was an annual 1-day session on optimal hypertension management. Total costs and effects were assessed at baseline and 2 years to estimate incremental costeffectiveness ratios based on (1) intervention cost; (2) cost of physician consultation, medications, diagnostics, changes in lifestyle, and productivity loss; and (3) change in systolic BP. We found that combined HHE plus GP intervention led to the most BP reduction for the cost (incremental cost-effectiveness ratio of $23 per mm Hg reduction in systolic BP compared with usual care) and remained so in 97.7% of 1000 bootstrapped replications. The estimated cost of the combined intervention was $115 per disability-adjusted life-year averted from the policymakers' perspective and $1226 per disability-adjusted life-year averted from the societal perspective; $0.43 per capita population per year would be needed to scale up the intervention in Pakistan. Thus, the combined intervention of GP training plus HHE intervention could potentially be an effective and affordable strategy for many low-and middle-income countries worldwide that are urgently in need of efforts to prevent and control hypertension.
Summary: Although the benefits of drug-eluting stents for reducing restenosis and repeat revascularization after percutaneous coronary intervention are well established, the optimal strategy for their use in clinical practice on both clinical and economic grounds is unknown. To address this gap in knowledge, we used data from a prospective, multicenter percutaneous coronary intervention registry to examine the clinical value and cost-effectiveness of liberal (2004 -2006) versus selective (2007) drug-eluting stent use strategies in 10 144 patients at 55 US centers. Over this time period, the use of drug-eluting stents decreased from 92% to 68% and coincided with an absolute increase of 1% in target lesion revascularization rates. Furthermore, these changes were associated with a reduction in cardiovascular costs of $401 per patient resulting mainly from reduced use of drug-eluting stents in the latter period. One-year rates of death or myocardial infarction were similar in both cohorts. The risk-adjusted incremental cost-effectiveness ratio for the liberal versus selective drug-eluting stent strategy was $16 000 per target lesion revascularization event avoided, $27 000 per repeat revascularization avoided, and $433 000 per quality-adjusted life-year gained. These findings suggest that although clinical outcomes are marginally better with unrestricted use of drug-eluting stents, this approach represents a relatively inefficient use of healthcare resources relative to several common benchmarks for cost-effective care.
Conclusions: In this prospective registry, a temporal reduction in drug-eluting stent use was associated with a small increase in target lesion revascularization and a modest reduction in total cardiovascular costs. These findings suggest that although clinical outcomes are marginally better with unrestricted drug-eluting stent use, this approach represents a relatively inefficient use of healthcare resources relative to several common benchmarks for cost-effective care. 2 Heart Association, healthcare professionals, hospitals, emergency medical services, and the research community, have focused on improving door-to-balloon times for patients with ST-segmentelevation myocardial infarction who are referred for an emergency percutaneous coronary intervention. We report the national experience in door-to-balloon times based on the Centers for Medicare & Medicaid Services' measure, which includes all patients of all ages. The door-to-balloon time declined from a median of 96 minutes in the year ending December 31, 2005, to a median of 64 minutes in the 3 quarters ending September 30, 2010. There were corresponding increases in the percentage of patients who had times Ͻ90 minutes (44.2%-91.4%) and Ͻ75 minutes (27.3%-70.4%). This improvement, experienced across the country and across different types of hospitals, represents a remarkable elevation in practice that was achieved over a relatively short period of time and in the absence of financial incentive. The improvement demonstrates the results that can be produced by collaboration among healthcare professionals, hospitals, and national organizations toward the achievement of a shared goal.
Conclusion: National progress has been achieved in the timeliness of treatment of patients with ST-segment-elevation myocardial infarction who undergo primary percutaneous coronary intervention. 3
The Need for Multiple Measures of Hospital Quality: Results From the Get With The Guidelines-Heart Failure Registry of the American Heart Association
Summary: Attention to the quality and value of health care has increased significantly in the United States with the passage the Affordable Care Act. Heart failure is one of the main areas targeted for improvement in quality and costs nationally. Prior studies have shown major gaps in the use of best therapies, and outcomes are poor. Although there is attention to improving processes of care and outcomes, it is unclear how these metrics of quality correlate with one another or whether hospitals should focus on one area to improve overall quality. This uncertainity also presents challenges to the public, hospitals, and policy makers in designing and participating in pay-for-performance health policies. By using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry linked with Medicare claims, we examined how profiling of hospitals is affected by different measures of quality of care. In general, agreement between different methods of ranking hospital-based quality of care and 30-day mortality or readmission rankings was poor. Profiling quality of care will require multidimensional ranking methods and/or additional measures.
Conclusions: Agreement between different methods of ranking hospital-based quality of care and 30-day mortality or readmission rankings was poor. Profiling quality of care will require multidimensional ranking methods and/or additional measures. 4
Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
Summary: This cost-effectiveness analysis sought to identify whether expanded use of statins for primary prevention would be cost-effective or even cost-saving in an era of generic, low-cost statins. Assuming that statins are universally available at a cost of $4/mo and efficacious in all persons Ͼ35 years of age, treatment thresholds of low-density lipoprotein cholesterol Ͼ160 mg/dL for low-risk persons (0 -1 risk factor), Ͼ130 mg/dL for moderate-risk persons (Ն2 risk factors and 10-year risk Ͻ10%), and Ͼ100 mg/dL for moderately high-risk persons (Ն2 risk factors and 10-year risk Ͼ10%) would reduce annual healthcare costs by $430 million compared with Adult Treatment Panel III guidelines. Lowering thresholds to Ͼ130 mg/dL for persons with 0 risk factors and Ͼ100 mg/dL for persons with 1 risk factor and treating all moderate-and moderately high-risk persons would further lower CHD burden for $9900 per quality-adjusted life-year compared with Adult Treatment Panel III guidelines. These findings were insensitive to known and hypothetical side effects, but were sensitive to large reductions in efficacy of statins or a long-term disutility burden for which a patient would trade 30 to 80 days of life to avoid 30 years of statins. Low-cost statins are cost-effective for most persons with even modestly elevated cholesterol or any coronary heart disease risk factors if they do not mind taking a pill daily.
Conclusions: Low-cost statins are cost-effective for most persons with even modestly elevated cholesterol or any coronary heart disease risk factors if they do not mind taking a pill daily. Adverse effects are unlikely to outweigh benefits in any subgroup in which statins are found to be efficacious. 5
Use of Emergency Medical Service Transport Among Patients With ST-Segment-Elevation Myocardial Infarction: Findings From the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With the Guidelines
Summary: Although current guidelines recommend activation of emergency medical services (EMS) for the expedited triage of patients experiencing cardiac chest pain, EMS has historically been underused. In this article, we explored the prevalence of EMS use among contemporary patients with ST-segment-elevation myocardial infarction, the sociodemographic and clinical factors associated with a patient's decision regarding mode of transport, and the differences in treatment between those patients who self-transport and those who use EMS. Examining the ST-segment-elevation myocardial infarction patients in the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines, we found that EMS remains underused, with only 60% of patients arriving to an emergency room via EMS. Patients who do not use EMS are more likely male, Hispanic, and younger than EMS users. The decision to use EMS was associated with at least a 30-minute reduction in symptom onset to arrival time, which is a substantial shortening of the total ischemic time. The decision to use EMS was also associated with reduced delays to in-hospital evaluation and reperfusion treatment. We believe our findings indicate a pressing need for community education efforts targeted at known demographic groups who underuse EMS transport. Furthermore, these efforts need to be integrated with system-wide strategies to improve reperfusion care.
Conclusions: Emergency medical services transportation to the hospital is underused among contemporary ST-segment-elevation myocardial infarction patients. Nevertheless, use of EMS transportation is associated with substantial reductions in ischemic time and treatment delays. Community education efforts are needed to improve the use of emergency transport as part of system-wide strategies to improve ST-segment-elevation myocardial infarction reperfusion care. 6
Differences in Admitting Hospital Characteristics for Black and White Medicare Beneficiaries With Acute Myocardial Infarction
Summary: Recent research has identified differential access to high-quality hospital care as an important, perhaps primary, factor associated with racial disparities in the treatment of acute myocardial infarction. However, the reasons why minorities are more often treated at hospitals with relatively lower quality of care are not fully understood. We examined the relationship between patient race, distance, and admissions to hospitals with particular characteristics (eg, provision of revascularization services, quality ranks) available to patients within defined hospital markets. We found that, after accounting for distance from home to available hospitals, black patients were overall less likely to be admitted to the closest hospitals, to hospitals with revascularization programs, and to high-quality hospitals. In secondary analyses limited to black and white patients living in similar ZIP codes, these differences were attenuated and not statistically significant. Our findings suggest that differences in admissions to hospitals with particular characteristics are not driven exclusively by race, but also by characteristics of the environment in which patients live. Such local context factors may include economic factors, community culture (eg, perceived discrimination, high levels of distrust in the healthcare system), and physician referral practices. Practicing physicians need to be aware of and sensitive to such potential local barriers in access to high-quality care.
Conclusions: Differences in admissions to revascularization and highquality hospitals may contribute to disparities in acute myocardial infarction care. These differences may be due in part to residential ZIP code characteristics. 7
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
Summary: The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial in patients with atrial fibrillation and at least 1 additional risk factor for stroke demonstrated that dabigatran 110 mg twice a day compared with warfarin was associated with a similar risk of stroke or systemic embolism and a lower risk of major bleeding, and that dabigatran 150 mg twice a day compared with warfarin was associated with a lower risk of stroke or systemic embolism and a similar risk of major bleeding. The effects of dabigatran compared with warfarin on stroke or systemic embolism were consistent in all subgroups examined, but there was a significant treatment-by-age interaction for major bleeding such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged Ͻ75 years and a similar risk in those aged Ն75 years, whereas dabigatran 150 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in those aged Ͻ75 years and a trend toward higher risk of major bleeding in those aged Ն75 years. The interaction between treatment and age was evident for extracranial bleeding but not for intracranial bleeding, which was consistently reduced with dabigatran compared with warfarin irrespective of age. These results suggest that in patients with atrial fibrillation and at least 1 additional risk factor for stroke who are aged Ͻ75 years, the higher dabigatran dose might be preferable, whereas in older patients, the lower dabigatran dose might be considered a means to reduce the risk of bleeding.
Conclusions:
In patients with atrial fibrillation at risk for stroke, both doses of dabigatran compared with warfarin have lower risks of both intracranial and extracranial bleeding in patients aged Ͻ75 years. In those aged Ն75 years, intracranial bleeding risk is lower but extracranial bleeding risk is similar or higher with both doses of dabigatran compared with warfarin. 8
Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study
Summary: Recently, there has been increased awareness of augmented cardiovascular risk associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs), especially among patients with established cardiovascular disease. Earlier studies have indicated acute or subacute effects of both the selective cyclooxygenase-2 inhibitors and nonselective NSAIDs on the cardiovascular system. These adverse events were closely tied to the timing of taking the drugs, and most patients were receiving treatment for a short period of time. However, at present, there is a lack of data on the impact of NSAID treatment duration on cardiovascular risk. The present study addresses the risk of all NSAIDs in a selected population of post-myocardial infarction patients. We present a comprehensive analysis of the effect of duration of NSAID treatment on risk of death or recurrent myocardial infarction in a nationwide cohort of myocardial infarction survivors. We found that short-term treatment with most NSAIDs was associated with increased and instantaneous cardiovascular risk. Particularly worrying was the fact that the widely used nonselective NSAID diclofenac was associated with early and higher cardiovascular risk than the selective cyclooxygenase-2 inhibitor rofecoxib, which was withdrawn from the market in 2004 owing to its unfavorable cardiovascular risk profile. Our results indicate that there is no apparent safe therapeutic window for NSAIDs in patients with prior myocardial infarction and challenge the current recommendations of short-term use of NSAIDs as being safe. We believe this message is important, and should be distributed as widely as possible to clinicians taking care of patients with cardiovascular disease.
Conclusions: Even short-term treatment with most NSAIDs was associated with increased risk of death and recurrent MI in patients with prior MI. Neither short-nor long-term treatment with NSAIDs is advised in this population, and any NSAID use should be limited from a cardiovascular safety point of view. 9
Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality
Summary: Heart failure (HF) is a chronic progressive disease that results in substantial morbidity, mortality, and expenditure of healthcare resources. Measuring and improving the quality of HF care is of high priority. Assessment of care quality has focused on the development and use of process-based performance measures, with the assumption that these process measures are associated with clinical outcomes. This association, however, has not previously been evaluated for current and emerging outpatient HF measures. In the present study, we used data from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) to examine the relationships between adherence to several HF process measures and clinical outcomes. Performance on 7 HF process measures and 2 summary measures was collected at baseline in patients from 167 US outpatient cardiology practices, with patients followed up for 24 months. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, ␤-blocker use, anticoagulant therapy for atrial fibrillation, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and HF education were each independently associated with improved 24-month survival, whereas aldosterone antagonist use was not. The all-or-none and composite care summary measures were also independently associated with improved survival. Each 10% improvement in composite care was associated with a 13% lower odds of 24-month mortality. This study suggests that current and some emerging outpatient HF process measures are positively associated with patient survival. Given the substantial burden of HF, the availability of well-validated process measures to accurately assess and improve the care of patients with HF is critical.
Conclusions: Current and emerging outpatient HF process measures are positively associated with patient survival. These HF measures may be useful for assessing and improving HF care. 10 tions to evaluate the efficacy and safety of these therapies in real world practice, often at the request of the Food and Drug Administration. However, few studies have examined whether patient characteristics and outcomes of PMS studies are truly representative of those treated in routine clinical practice. In this study from the National Cardiovascular Database Registry-Carotid Artery Revascularization and Endarterectomy (NCDR CARE) registry, the authors compared clinical characteristics and outcomes of patients undergoing carotid artery stenting (CAS) enrolled in postmarketing studies to those not enrolled in such studies. PMS study participants had overall less severe neurological disease histories, better in-hospital outcomes, and lower long-term mortality rates compared to nonparticipants, even after propensity-score adjustment. The findings suggest that PMS studies of CAS include a healthier population of patients than those undergoing CAS in routine practice, and that extrapolating results from PMS studies of CAS to larger real world settings may not be appropriate. They also further confirm the importance of large inclusive disease registries with minimal exclusion criteria to properly evaluate the safety and efficacy of newly disseminated technologies in routine practice.
Conclusions:
Participants in PMS studies for carotid artery stenting have different clinical and procedural characteristics and lower mortality compared with nonparticipants. Extrapolating results from PMS studies of carotid artery stenting to larger real-world settings should be done only with great caution. 11
Secondary Prevention After Coronary Artery Bypass Graft Surgery: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation Into Practice
Summary: This randomized controlled trial rigorously tests, on a national scale, whether low-intensity continuous quality improvement interventions can be used to speed secondary prevention adherence after coronary artery bypass graft surgery. A total of 458 hospitals participating in the Society of Thoracic Surgeons National Cardiac Database and treating 361 328 patients undergoing isolated coronary artery bypass graft surgery were randomized to either a control or an intervention group. The intervention group received continuous quality improvement materials designed to influence the prescription of the secondary prevention medications at discharge. The primary outcome measure of the study was discharge prescription rates of the targeted secondary prevention medications at intervention versus control sites, assessed by measuring preintervention and postintervention site differences. Prerandomization treatment patterns and baseline data were similar in the control (nϭ234) and treatment (nϭ224) groups. Individual medication use and composite adherence increased over 24 months in both groups, with a markedly more rapid rate of adherence uptake among the intervention hospitals and a statistically significant therapy hazard ratio in the intervention versus control group for all recommended secondary prevention medications. Thus, we conclude that provider-led, low-intensity continuous quality improvement efforts can improve the adoption of clinical care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement.
Conclusions: Provider-led, low-intensity continuous quality improvement efforts can improve the adoption of care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement. 12
Trends in Out-of-Hospital Deaths Due to Coronary Heart Disease in Sweden (1991-2006)
Summary: One of the most frightening aspects of coronary heart disease is that many people die suddenly, out of the hospital, and with little or no warning. With modern treatment and with decreasing case severity in hospitalized cases, hospital mortality, at least among younger patients, is now low, and the in-hospital course is very different from the large untreated infarctions of the early 1980s and before. Accordingly, the true seriousness of coronary disease may be underestimated by younger members of the medical profession. The Swedish registers, with national, almost complete coverage and the possibility of linking hospital and death registries through personal identifiers, provide unique opportunities to investigate this issue. In a study of trends in out-of-hospital deaths due to coronary heart disease in Sweden from 1991 to 2006, among 384 597 first events, it was confirmed that the great majority of all fatal coronary events occur outside the hospital and that this proportion is increasing, particularly among younger individuals: Almost 9 of 10 fatal first events now occur in persons not admitted to a hospital. The autopsy rate for these young individuals was 81%, which implies that misclassification is probably minor. To achieve further reduction in coronary heart disease-related case fatality, primary prevention is increasingly more important, as are efforts to persuade individuals to seek hospital treatment as soon as symptoms of a major coronary event occur. There is an important public health message in these data, as well as a message for the medical profession.
Conclusions:
The great majority of all fatal coronary events occur outside the hospital, and this proportion is increasing, particularly among younger individuals. 13
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
Summary: Both nonhigh-density lipoprotein cholesterol (Non-HDL-C) (the total mass of cholesterol within the very-low-density lipoprotein [LDL] and LDL particles) and apolipoprotein B (apoB) (the total number of atherogenic apoB lipoprotein particles) have been suggested to be more accurate markers than LDL cholesterol (LDL-C) of the risk of vascular disease. The results of individual published studies have not yielded a consistent result, particularly with regard to the relative predictive powers of non-HDL-C and apoB. The present study is a meta-analysis of all the published studies reporting estimates of the relative risks of non-HDL-C and apoB of fatal and nonfatal ischemic vascular events. Whether analyzed individually or head to head, apoB was the most potent marker of risk, LDL-C was the least, and non-HDL-C was intermediate. This study indicates that apoB is superior to LDL-C and non-HDL-C as a predictor of cardiovascular risk.
Conclusions: These results further validate the value of apoB in clinical care. 14 Conclusions: Prehospital, emergency department, and hospital processes of care were independently associated with shorter door-in-doorout times for STEMI patients requiring transfer. Adoption of several emergency medical services processes was associated with the largest reduction in treatment times. These findings highlight the need for an integrated, system-based approach to improving STEMI care. 16 
Trends in Coronary Revascularization in the United States From 2001 to 2009: Recent Declines in Percutaneous Coronary Intervention Volumes

Community Outreach and Cardiovascular Health (COACH) Trial: A Randomized, Controlled Trial of Nurse Practitioner/Community Health Worker Cardiovascular Disease Risk Reduction in Urban Community Health Centers
Summary: Despite well-publicized guidelines on the appropriate management of cardiovascular disease and type 2 diabetes, the implementation of risk-reducing practices remains poor, especially in high-risk vulnerable populations. Case management by a specially trained nurse-led team is one of the most efficacious strategies to improve cardiovascular disease risk factor management. An intervention delivered by a nurse practitioner/community health worker team using individualized treatment regimens based on treat-totarget algorithms improved cardiovascular disease risk factor status and perceptions of chronic illness care. The results of this trial support nurse-led patient-centered medical homes to improve the quality of cardiovascular disease care in high risk underserved populations.
Conclusions: An intervention delivered by a nurse practitioner/ community health worker team using individualized treatment regimens based on treat-to-target algorithms can be an effective approach to improve risk factor status and perceptions of chronic illness care in high-risk patients. 17
Who Has Higher Readmission Rates for Heart Failure, and Why? Implications for Efforts to Improve Care Using Financial Incentives
Summary: Decreasing readmissions is seen as having the potential to simultaneously lower costs and improve quality and therefore has become an important target for policymakers. There is significant variability in hospitals' performance on readmission rates across the nation; little is known about why some hospitals perform well whereas others perform poorly. Legislative efforts in this area, including the recently passed Patient Protection and Affordable Care Act, focus on reducing payments to those with the highest readmission rates; if poorly performing hospitals are also resource-poor, either financially or clinically, these payment reductions could lead to an increase in existing gaps in performance. Hospitals with limited resources, either financial, clinical, or both, namely publicly owned hospitals, hospitals located in counties with low median income, hospitals with fewer cardiac capabilities or lower nurse staffing levels, and small hospitals, had higher readmission rates for heart failure. Thus, because some of the most financially and clinically resource-poor hospitals in the country are among the worst performers for heart failure readmissions, quality improvement efforts that rely on penalties and rewards may further widen the quality gap.
Conclusions:
Given that many poor-performing hospitals also have fewer resources, they may suffer disproportionately from financial penalties for high readmission rates. As we seek to improve care for patients with heart failure, we should ensure that penalties for poor performance do not worsen disparities in quality of care. 18 
